Science Explorer Back to mapMap
Institution · PharmaMar (Spain)

Most cited papers from PharmaMar (Spain)

What are the most cited papers from PharmaMar (Spain)?

The most cited paper from PharmaMar (Spain) is "Role of Macrophage Targeting in the Antitumor Activity of Trabectedin" (Giovanni Germano et al., 2013), with 874 citations. Next come "The odyssey of marine pharmaceuticals: a current pipeline perspective" (669) and "Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules" (537).

Showing 50 of 60 papers. Every paper with more than 99 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Role of Macrophage Targeting in the Antitumor Activity of Trabectedin Giovanni Germano et al. · Cancer Cell Open access Feb 2013 874
2 The odyssey of marine pharmaceuticals: a current pipeline perspective Alejandro M. S. Mayer, Keith B. Glaser, Carmen Cuevas et al. · Trends in Pharmacological Sciences 6 Apr 2010 669
3 Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules George D. Demetri, Sant P. Chawla, Margaret von Mehren et al. · Journal of Clinical Oncology Open access 4 Aug 2009 537
4 Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial José Manuel Trigo et al. · The Lancet Oncology 27 Mar 2020 488
5 Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study Federica Grosso, Robin L. Jones, George D. Demetri et al. · The Lancet Oncology 23 Jun 2007 452
6 A Review of Trabectedin (ET-743): A Unique Mechanism of Action Maurizio D’Incalci, Carlos María Galmarini · Molecular Cancer Therapeutics 20 Jul 2010 450
7 A comparison between two brine shrimp assays to detect in vitrocytotoxicity in marine natural products José Luís Carballo, Zaira L Hernández-Inda, Pilar Pérez et al. · BMC Biotechnology Open access 23 Sep 2002 403
8 Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A Kris M. White et al. · Science Open access 25 Feb 2021 368
9 Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead William H. Goodson et al. · Carcinogenesis Open access173 authors Jun 2015 324
10 Development of Yondelis® (trabectedin, ET-743). A semisynthetic process solves the supply problem Carmen Cuevas, Andrés Francesch · Natural Product Reports 2009 322
11 Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy Rocio García‐Carbonero, Jeff Supko, Judith B. Manola et al. · Journal of Clinical Oncology Open access 14 Apr 2004 294
12 Synthesis of Ecteinascidin ET-743 and Phthalascidin Pt-650 from Cyanosafracin B Carmen Cuevas, Marta del Pozo Pérez, María Jesús Martín et al. · Organic Letters 19 Jul 2000 283
13 A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs Andrea Enrico Prota, Katja Bargsten, José Fernando Díaz et al. · Proceedings of the National Academy of Sciences Open access 11 Aug 2014 282
14 Conjugate addition reactions of carbon nucleophiles to electron-deficient dienes Aurelio G. Csákÿ, Gabriela de la Herrán, M. Carmen Murcia · Chemical Society Reviews Review 2010 278
15 Antitumor and Anti-inflammatory Effects of Trabectedin on Human Myxoid Liposarcoma Cells Giovanni Germano et al. · Cancer Research Open access 9 Mar 2010 267
16 Marine organisms as a source of new anticancer agents Gilberto Schwartsmann, Adriana Brondani da Rocha, Roberto G. S. Berlinck et al. · The Lancet Oncology Apr 2001 263
17 Thiocoraline, a New Depsipeptide with Antitumor Activity Produced by a Marine Micromonospora. I. Taxonomy, Fermentation, Isolation, and Biological Activities. Francisco Romero, FERNANDO ESPLIEGO, JULIA PÉREZ BAZ et al. · The Journal of Antibiotics Open access 1997 226
18 Trabectedin, a drug acting on both cancer cells and the tumour microenvironment Maurizio D’Incalci, N Badri, Carlos María Galmarini et al. · British Journal of Cancer Open access 22 Apr 2014 219
19 Lamellarin D: a novel potent inhibitor of topoisomerase I. Michaël Facompré, Christelle Tardy, Christine Bal-Mahieu et al. · PubMed Nov 2003 192
20 Ecteinascidin-743 (ET-743) for Chemotherapy-Naive Patients With Advanced Soft Tissue Sarcomas: Multicenter Phase II and Pharmacokinetic Study Rocio García‐Carbonero, Jeffrey G. Supko, Robert G. Maki et al. · Journal of Clinical Oncology 18 Aug 2005 191
21 Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Yajaira Suárez, Laura González, Ana Cuadrado et al. · PubMed Sep 2003 191
22 Deciphering the Biosynthesis Pathway of the Antitumor Thiocoraline from a Marine Actinomycete and Its Expression in Two Streptomyces Species Felipe Lombó, Ana Luisa Velasco, Angelina D. Castro et al. · ChemBioChem 12 Jan 2006 184
23 Circulating tumor cells predict progression free survival and overall survival in patients with relapsed/recurrent advanced ovarian cancer Andres M. Poveda, Stanley B. Kaye, Robert Thomas Mccormack et al. · Gynecologic Oncology 25 Jun 2011 182
24 New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials José María Jimeno, Glynn T Faircloth, JM Fernández Sousa-Faro et al. · Marine Drugs Open access 25 Feb 2004 180
25 Unique features of trabectedin mechanism of action Annette Kragh Larsen, Carlos María Galmarini, Maurizio D’Incalci · Cancer Chemotherapy and Pharmacology 14 Dec 2015 173
26 Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial Andres M. Poveda, Ignace B. Vergote, Sergei Tjulandin et al. · Annals of Oncology Open access 20 Jul 2010 170
27 Gold Glyconanoparticles as New Tools in Antiadhesive Therapy Javier Rojo, Vicente M. Diaz, Jesús Martínez de la Fuente et al. · ChemBioChem 26 Feb 2004 169
28 Prevalencia de osteoporosis determinada por densitometría en la población femenina española Díaz Curiel M, Javier Garcia, José Luís Carrasco et al. · Medicina Clínica 2001 169
29 Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells Gema Santamaría Núñez, Carlos Mario Genes Robles, Christophe Giraudon et al. · Molecular Cancer Therapeutics 14 Sep 2016 163
30 Cancer Cell Mitochondria Are Direct Proapoptotic Targets for the Marine Antitumor Drug Lamellarin D Jérôme Kluza, Miguel-Angel Gallego, Anne Loyens et al. · Cancer Research 15 Mar 2006 161
31 AplidinTM Induces Apoptosis in Human Cancer Cells via Glutathione Depletion and Sustained Activation of the Epidermal Growth Factor Receptor, Src, JNK, and p38 MAPK Ana Cuadrado, Luis García‐Fernández, Laura González et al. · Journal of Biological Chemistry Open access 28 Dec 2002 158
32 PM01183, a new DNA minor groove covalent binder with potent in vitro and in vivo anti‐tumour activity JFM Leal, Marta Martínez, Verónica García-Hernández et al. · British Journal of Pharmacology Open access 2 Jul 2010 158
33 Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models Cristina Belgiovine, Ezia Bello, Manuela Liguori et al. · British Journal of Cancer Open access 6 Jul 2017 157
34 Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites Rubén M. Buey, Enrique Calvo, Isabel Barasoaı́n et al. · Nature Chemical Biology 7 Jan 2007 153
35 Progress in the development and acquisition of anticancer agents from marine sources Maria Luz Amador, José María Jimeno, Luis G Paz-Ares et al. · Annals of Oncology Open access 28 Oct 2003 152
36 The marine compound spisulosine, an inhibitor of cell proliferation, promotes the disassembly of actin stress fibers Raquel Cuadros, Esteban Montejo de Garcini, Francisco G. Wandosell et al. · Cancer Letters Apr 2000 151
37 Structure−Activity Relationships of the Didemnins Ryuichi Sakai, Kenneth L. Rinehart, Vimal Kishore et al. · Journal of Medicinal Chemistry 1996 150
38 Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma Alessandro Gronchi, B. Bui, Sylvie Bonvalot et al. · Annals of Oncology Open access 4 Jun 2011 148
39 Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4 Massimo Broggini, Sergio Marchini, Emanuela Galliera et al. · Leukemia 2003 146
40 A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas Axel Le Cesne, Sara Cresta, Robert G. Maki et al. · European Journal of Cancer Open access 29 Jun 2012 143
41 In vitro antitumor activity of the novel marine agent, Ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients Elżbieta Izbicka, Rachel A. Lawrence, Éric Raymond et al. · Annals of Oncology Open access Sep 1998 136
42 Aplidin™ induces the mitochondrial apoptotic pathway via oxidative stress-mediated JNK and p38 activation and protein kinase C δ Luis García‐Fernández, Alejandro Losada, Victoria Alcaide et al. · Oncogene 18 Oct 2002 136
43 Thiocoraline, a Novel Depsipeptide with Antitumor Activity Produced by a Marine Micromonospora. II. Physico-chemical Properties and Structure Determination. JULIA PÉREZ BAZ, Librada M. Cañedo, JOSÉ L. FERNÁNDEZ PUENTES et al. · The Journal of Antibiotics Open access 1997 136
44 Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series Federica Grosso, Roberta G. Sanfilippo, Emanuela Virdis et al. · Annals of Oncology Open access 23 May 2009 131
45 Mode of action of trabectedin in myxoid liposarcomas Silvia Di Giandomenico, Roberta Frapolli, Ezia Bello et al. · Oncogene 11 Nov 2013 130
46 Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial Santiago Ponce Aix et al. · The Lancet Respiratory Medicine Open access 14 Oct 2022 125
47 Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas Jean‐Yves Blay, Michael Gordon Leahy, Binh Bui Nguyen et al. · European Journal of Cancer Open access 7 Feb 2014 121
48 SARS-CoV-2 variants evolve convergent strategies to remodel the host response Mehdi Bouhaddou et al. · Cell Open access 21 Sep 2023 117
49 Batzelladine alkaloids from the caribbean sponge Monanchora unguifera and the significant activities against HIV-1 and AIDS opportunistic infectious pathogens Huiming Hua, Jiangnan Peng, D. Chuck Dunbar et al. · Tetrahedron 9 Aug 2007 115
50 Isolation and First Total Synthesis of PM050489 and PM060184, Two New Marine Anticancer Compounds María Jesús Martín, Laura Coello, Rogelio Fernández et al. · Journal of the American Chemical Society 10 Jun 2013 114

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.